SHORTEN-2 trial
@shorten2trial.bsky.social
RCT 7 vs 14 days of treatment for P. aeruginosa BSI.
Updated trial progress and #FOAMed on P. aeruginosa.
#AMSSky #IDSky #PsWatch
Powered by @guiaprioam.bsky.social
📚 Full protocol: https://shorturl.at/xN0wj
🌐 https://clinicaltrials.gov/study/NCT05210439
Updated trial progress and #FOAMed on P. aeruginosa.
#AMSSky #IDSky #PsWatch
Powered by @guiaprioam.bsky.social
📚 Full protocol: https://shorturl.at/xN0wj
🌐 https://clinicaltrials.gov/study/NCT05210439
Pinned
Our @shorten2trial.bsky.social aims to confirm that 7-day treatments are superior to 14-day courses for uncomplicated P. aeruginosa BSI.
Check out our full protocol 👉🏻 journals.plos.org/plosone/arti...
#AMSsky #IDSky
Check out our full protocol 👉🏻 journals.plos.org/plosone/arti...
#AMSsky #IDSky
Reposted by SHORTEN-2 trial
¿Trabajas en consulta?
¡Te necesitamos!
Durante toda esta semana, no te pierdas nuestra serie de vídeos prácticos para hacer un uso prudente de los antibióticos en tus pacientes ambulatorios
👊🏻 La lucha contra las resistencias, empieza en tu consulta
#EAAD #WAAW #AMSsky #MedSky #PharmSky #SomosHUVR
¡Te necesitamos!
Durante toda esta semana, no te pierdas nuestra serie de vídeos prácticos para hacer un uso prudente de los antibióticos en tus pacientes ambulatorios
👊🏻 La lucha contra las resistencias, empieza en tu consulta
#EAAD #WAAW #AMSsky #MedSky #PharmSky #SomosHUVR
November 18, 2025 at 7:54 AM
Reposted by SHORTEN-2 trial
Recruitment for SHORTEN-2 is officially complete!
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
October 18, 2025 at 9:57 AM
Recruitment for SHORTEN-2 is officially complete!
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
Reposted by SHORTEN-2 trial
Fantastic - this will be an impactful study on treatment duration of blood stream Pseudomonas infection.
Our centre already mostly does 7 days (and my prediction is that this will be non-inferior) but it's RCT like these that will shift dial across the board with persuasive evidence.
#IDSky #AMR
Our centre already mostly does 7 days (and my prediction is that this will be non-inferior) but it's RCT like these that will shift dial across the board with persuasive evidence.
#IDSky #AMR
Recruitment for SHORTEN-2 is officially complete!
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
October 18, 2025 at 11:37 AM
Recruitment for SHORTEN-2 is officially complete!
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
October 18, 2025 at 9:57 AM
Recruitment for SHORTEN-2 is officially complete!
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
Our team is now wrapping up follow-up and polishing databases. Hope to have results ready in the first half of 2026!
Hats off to this awesome research team! 🥳
#AMSsky #IDsky @seimc.bsky.social @ciberisciii.bsky.social @ibis-investigacion.bsky.social
Reposted by SHORTEN-2 trial
It’s encouraging to see new guidelines moving toward shorter and fully-oral treatments for BSIs.
We are honoured to see some of our research cited to help shape these recommendations! 😃
#AMSsky #IDsky #UTIsky @hospitaluvrocio.bsky.social @ibis-investigacion.bsky.social bsky.app/profile/jose...
We are honoured to see some of our research cited to help shape these recommendations! 😃
#AMSsky #IDsky #UTIsky @hospitaluvrocio.bsky.social @ibis-investigacion.bsky.social bsky.app/profile/jose...
Can we treat patients with low-risk BSI discharged from the ED with a fully-oral course of antibiotics?
[Spoiler: Yes!]
🆓🔓Our recent article on #OralIsTheNewIV! 👉🏻 journals.asm.org/doi/10.1128/...
Food for thought for #AMSsky #IDSky
[Spoiler: Yes!]
🆓🔓Our recent article on #OralIsTheNewIV! 👉🏻 journals.asm.org/doi/10.1128/...
Food for thought for #AMSsky #IDSky
Safety of early oral ambulatory treatment of adult patients with bloodstream infections discharged from the emergency department | Antimicrobial Agents and Chemotherapy
Randomized trials have unanimously shown the benefits of oral antibiotic treatments for stable patients with bacteremia (1). However, transition to oral therapy has been usually performed after several days of intravenous treatment—frequently up to 7 days (2)—highlighting the need for evidence of the safety of earlier oral treatments (3).
journals.asm.org
July 19, 2025 at 9:00 AM
It’s encouraging to see new guidelines moving toward shorter and fully-oral treatments for BSIs.
We are honoured to see some of our research cited to help shape these recommendations! 😃
#AMSsky #IDsky #UTIsky @hospitaluvrocio.bsky.social @ibis-investigacion.bsky.social bsky.app/profile/jose...
We are honoured to see some of our research cited to help shape these recommendations! 😃
#AMSsky #IDsky #UTIsky @hospitaluvrocio.bsky.social @ibis-investigacion.bsky.social bsky.app/profile/jose...
This metaanalysis of observational studies in SOT suggests that non-complicated graft infections could be treated 7d, and yet transplant patients have been excluded from most RCT on duration.
Time for a #ShorterIsBetter RCT in #TxID!
kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F... #IDsky #AMSsky
Time for a #ShorterIsBetter RCT in #TxID!
kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F... #IDsky #AMSsky
July 4, 2025 at 10:44 PM
This metaanalysis of observational studies in SOT suggests that non-complicated graft infections could be treated 7d, and yet transplant patients have been excluded from most RCT on duration.
Time for a #ShorterIsBetter RCT in #TxID!
kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F... #IDsky #AMSsky
Time for a #ShorterIsBetter RCT in #TxID!
kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F... #IDsky #AMSsky
Reposted by SHORTEN-2 trial
Check out this cool collaboration with @hernando-amado.bsky.social, just out in @natcomms.nature.com!
We show that ciprofloxacin resistance rapidly declines in clinical P. aeruginosa strains under drug-free conditions, suggesting that ciprofloxacin restriction periods could help in clinics 🦠🧫
We show that ciprofloxacin resistance rapidly declines in clinical P. aeruginosa strains under drug-free conditions, suggesting that ciprofloxacin restriction periods could help in clinics 🦠🧫
I am very happy to share our latest study on ciprofloxacin resistance instability in P. aeruginosa during periods of drug restriction. A fantastic collaboration @pablolaborda.bsky.social, RuggeroLaRosa, JLMartínez, SørenMolin & HelleJohansen 🥳 @cnb-csic.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Ciprofloxacin resistance rapidly declines in nfxB defective clinical strains of Pseudomonas aeruginosa - Nature Communications
Antimicrobial resistance can decline due to compensatory mutations or genetic reversions to wild-type alleles. Here, the authors analyse the decline of ciprofloxacin resistance in nfxB-defective Pseud...
www.nature.com
June 4, 2025 at 9:38 AM
Check out this cool collaboration with @hernando-amado.bsky.social, just out in @natcomms.nature.com!
We show that ciprofloxacin resistance rapidly declines in clinical P. aeruginosa strains under drug-free conditions, suggesting that ciprofloxacin restriction periods could help in clinics 🦠🧫
We show that ciprofloxacin resistance rapidly declines in clinical P. aeruginosa strains under drug-free conditions, suggesting that ciprofloxacin restriction periods could help in clinics 🦠🧫
Reposted by SHORTEN-2 trial
Variability in Durations of Therapy for Gram-Negative Bloodstream Infections and Factors Associated with Prolonged Durations
✅ Just Accepted
⭐ Editor's Choice
#IDSky
✅ Just Accepted
⭐ Editor's Choice
#IDSky
Variability in Durations of Therapy for Gram-Negative Bloodstream Infections and Factors Associated with Prolonged Durations
In this study of 4,240 GN-BSI episodes during 2019 from 24 U.S. hospitals, the median duration of therapy was 12 days (IQR 9-15); 59% were treated for >10 days. There was marked variability in treatment durations across hospitals.
doi.org
May 24, 2025 at 2:33 PM
Variability in Durations of Therapy for Gram-Negative Bloodstream Infections and Factors Associated with Prolonged Durations
✅ Just Accepted
⭐ Editor's Choice
#IDSky
✅ Just Accepted
⭐ Editor's Choice
#IDSky
Today we celebrated our 3rd Annual Researchers’ Meeting at the XXVIII Congress of @seimc.bsky.social!
Only 2️⃣4️⃣ patients left to complete the trial!
An amazing team doing an amazing work! 🤩🔝
#IDSky #AMSsky #TeamPride
Only 2️⃣4️⃣ patients left to complete the trial!
An amazing team doing an amazing work! 🤩🔝
#IDSky #AMSsky #TeamPride
May 23, 2025 at 4:49 PM
Today we celebrated our 3rd Annual Researchers’ Meeting at the XXVIII Congress of @seimc.bsky.social!
Only 2️⃣4️⃣ patients left to complete the trial!
An amazing team doing an amazing work! 🤩🔝
#IDSky #AMSsky #TeamPride
Only 2️⃣4️⃣ patients left to complete the trial!
An amazing team doing an amazing work! 🤩🔝
#IDSky #AMSsky #TeamPride
Reposted by SHORTEN-2 trial
Sociodemographic features have a strong influence on antibiotic use, and yet antimicrobial stewardship trials showed the lowest reporting rates of these data among RCTs in this systematic review.
Fantastic work @seanong.bsky.social! An important heads-up for #AMSsky #IDsky researchers 💪🏼
Fantastic work @seanong.bsky.social! An important heads-up for #AMSsky #IDsky researchers 💪🏼
Our new paper in @cmijournal.bsky.social, a systematic review where we evaluated reporting of baseline sociodemographic characteristics across 1343 ID clinical trials over a 10-year period. A 🧵:
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
Redirecting
doi.org
May 7, 2025 at 5:33 AM
Sociodemographic features have a strong influence on antibiotic use, and yet antimicrobial stewardship trials showed the lowest reporting rates of these data among RCTs in this systematic review.
Fantastic work @seanong.bsky.social! An important heads-up for #AMSsky #IDsky researchers 💪🏼
Fantastic work @seanong.bsky.social! An important heads-up for #AMSsky #IDsky researchers 💪🏼
Reposted by SHORTEN-2 trial
Caring for patients with bronchiectasis poses a challenge for both pulmonologists and #AMSky teams.
Standard 14d treatments for exacerbations lack good evidence support.
This small RCT favors shorter durations such as 8d 👉🏻 publications.ersnet.org/content/erj/... #IDsky @bradspellberg.bsky.social
Standard 14d treatments for exacerbations lack good evidence support.
This small RCT favors shorter durations such as 8d 👉🏻 publications.ersnet.org/content/erj/... #IDsky @bradspellberg.bsky.social
May 4, 2025 at 12:43 AM
Caring for patients with bronchiectasis poses a challenge for both pulmonologists and #AMSky teams.
Standard 14d treatments for exacerbations lack good evidence support.
This small RCT favors shorter durations such as 8d 👉🏻 publications.ersnet.org/content/erj/... #IDsky @bradspellberg.bsky.social
Standard 14d treatments for exacerbations lack good evidence support.
This small RCT favors shorter durations such as 8d 👉🏻 publications.ersnet.org/content/erj/... #IDsky @bradspellberg.bsky.social
Reposted by SHORTEN-2 trial
Fascinating and important study. May well be transformative in treatment of stubborn chronic lung infections such as by Pseudomonas aeruginosa in #cysticfibrosis and beyond
rdcu.be/ekdWf
rdcu.be/ekdWf
Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis
Nature Medicine - A novel personalized phage therapy strategy that selects phages for a predicted evolutionary trade-off may represent a viable alternative approach for the treatment of...
rdcu.be
May 1, 2025 at 9:15 AM
Fascinating and important study. May well be transformative in treatment of stubborn chronic lung infections such as by Pseudomonas aeruginosa in #cysticfibrosis and beyond
rdcu.be/ekdWf
rdcu.be/ekdWf
Reposted by SHORTEN-2 trial
Calling all statisticians: we need your help. We'll soon be running an RCT comparing ceftazidime + iv fosfomycin to ceftaz alone in septic patients. Our hospital's stats unit is small & overworked. If you're available to freelance, we have a budget for this! #IDSky #Clinmicro #EpiSky #MedSky (1/2)
April 16, 2025 at 5:22 PM
Calling all statisticians: we need your help. We'll soon be running an RCT comparing ceftazidime + iv fosfomycin to ceftaz alone in septic patients. Our hospital's stats unit is small & overworked. If you're available to freelance, we have a budget for this! #IDSky #Clinmicro #EpiSky #MedSky (1/2)
SOT patients have been systematically excluded from most RCTs on treatment duration, leading to prolonged courses still being the standard of care in many centers, even for non-complicated infections.
(🧵1/3) #AMSky #IDsky #TxID
(🧵1/3) #AMSky #IDsky #TxID
🆕💫Large Multicentre cohort study
Epidemiology, Treatment, and Outcomes of Gram-Negative Bacteremia in Solid Organ Transplant Recipients #IDsky
onlinelibrary.wiley.com/doi/full/10....
Epidemiology, Treatment, and Outcomes of Gram-Negative Bacteremia in Solid Organ Transplant Recipients #IDsky
onlinelibrary.wiley.com/doi/full/10....
April 29, 2025 at 10:10 PM
Reposted by SHORTEN-2 trial
2025 Update of SPIRIT guidelines for RCT protocols: www.thelancet.com/action/showP... #IDSky #Medsky
April 29, 2025 at 9:58 PM
2025 Update of SPIRIT guidelines for RCT protocols: www.thelancet.com/action/showP... #IDSky #Medsky
Reposted by SHORTEN-2 trial
To change or not to change?
The necessity of replacing a catheter during a CAUTI remains a subject of ongoing debate. Please fill in this survey to help us assess potential global practice variation in catheter management!
Completion only takes <2 minutes: forms.office.com/e/MRCMwUb2UK
The necessity of replacing a catheter during a CAUTI remains a subject of ongoing debate. Please fill in this survey to help us assess potential global practice variation in catheter management!
Completion only takes <2 minutes: forms.office.com/e/MRCMwUb2UK
March 22, 2025 at 7:32 AM
To change or not to change?
The necessity of replacing a catheter during a CAUTI remains a subject of ongoing debate. Please fill in this survey to help us assess potential global practice variation in catheter management!
Completion only takes <2 minutes: forms.office.com/e/MRCMwUb2UK
The necessity of replacing a catheter during a CAUTI remains a subject of ongoing debate. Please fill in this survey to help us assess potential global practice variation in catheter management!
Completion only takes <2 minutes: forms.office.com/e/MRCMwUb2UK
Reposted by SHORTEN-2 trial
6/ Además, hablamos de SHORTEN2, un estudio que dará mucho que hablar próximamente. 🔜📊
t.co/5whVazbnTo
t.co/5whVazbnTo
https://pmc.ncbi.nlm.nih.gov/articles/PMC9778939/
t.co
February 15, 2025 at 7:31 PM
6/ Además, hablamos de SHORTEN2, un estudio que dará mucho que hablar próximamente. 🔜📊
t.co/5whVazbnTo
t.co/5whVazbnTo
Reposted by SHORTEN-2 trial
🎙️💊 Sensible y Resistente - Episodio 1
@micromunidad.bsky.social
¿Hasta qué punto importa la duración del tratamiento antibiótico? 🧐
open.spotify.com/episode/4yak31…
Hilo con claves y artículos 📚👇#AMSskyk#IDskyky
@micromunidad.bsky.social
¿Hasta qué punto importa la duración del tratamiento antibiótico? 🧐
open.spotify.com/episode/4yak31…
Hilo con claves y artículos 📚👇#AMSskyk#IDskyky
https://open.spotify.com/episode/4yak31…
February 15, 2025 at 7:31 PM
🎙️💊 Sensible y Resistente - Episodio 1
@micromunidad.bsky.social
¿Hasta qué punto importa la duración del tratamiento antibiótico? 🧐
open.spotify.com/episode/4yak31…
Hilo con claves y artículos 📚👇#AMSskyk#IDskyky
@micromunidad.bsky.social
¿Hasta qué punto importa la duración del tratamiento antibiótico? 🧐
open.spotify.com/episode/4yak31…
Hilo con claves y artículos 📚👇#AMSskyk#IDskyky
Reposted by SHORTEN-2 trial
Systematic review of antibiotic durations in @jac-amr.bsky.social
n=315 RCTs
85% demonstrated equivalence or non-inferiority of shorter therapy
Only 7% in ICU, 14% in LMIC, and 15% low risk of bias
academic.oup.com/jacamr/artic...
n=315 RCTs
85% demonstrated equivalence or non-inferiority of shorter therapy
Only 7% in ICU, 14% in LMIC, and 15% low risk of bias
academic.oup.com/jacamr/artic...
January 30, 2025 at 4:47 AM
Systematic review of antibiotic durations in @jac-amr.bsky.social
n=315 RCTs
85% demonstrated equivalence or non-inferiority of shorter therapy
Only 7% in ICU, 14% in LMIC, and 15% low risk of bias
academic.oup.com/jacamr/artic...
n=315 RCTs
85% demonstrated equivalence or non-inferiority of shorter therapy
Only 7% in ICU, 14% in LMIC, and 15% low risk of bias
academic.oup.com/jacamr/artic...
Reposted by SHORTEN-2 trial
Haven't posted about SNAP for a while:
But we've just hit 4000 participants. Almost at 3 years since opening.
And submitting two late breaker oral abstracts to ESCMID Global. @escmid.bsky.social
Amazing progress and more to come.
@gurujosh.bsky.social @drtoddlee.bsky.social
But we've just hit 4000 participants. Almost at 3 years since opening.
And submitting two late breaker oral abstracts to ESCMID Global. @escmid.bsky.social
Amazing progress and more to come.
@gurujosh.bsky.social @drtoddlee.bsky.social
February 9, 2025 at 10:16 AM
Haven't posted about SNAP for a while:
But we've just hit 4000 participants. Almost at 3 years since opening.
And submitting two late breaker oral abstracts to ESCMID Global. @escmid.bsky.social
Amazing progress and more to come.
@gurujosh.bsky.social @drtoddlee.bsky.social
But we've just hit 4000 participants. Almost at 3 years since opening.
And submitting two late breaker oral abstracts to ESCMID Global. @escmid.bsky.social
Amazing progress and more to come.
@gurujosh.bsky.social @drtoddlee.bsky.social
Reposted by SHORTEN-2 trial
Shorter is greener! 🍃♻️
Unnecessary antibiotics contribute to greenhouse gas emmissions. Want to know how much? 👉🏻 shorturl.at/52wOT
Fantastic point! #IDSky #AMSsky
Unnecessary antibiotics contribute to greenhouse gas emmissions. Want to know how much? 👉🏻 shorturl.at/52wOT
Fantastic point! #IDSky #AMSsky
February 12, 2025 at 11:43 PM
Shorter is greener! 🍃♻️
Unnecessary antibiotics contribute to greenhouse gas emmissions. Want to know how much? 👉🏻 shorturl.at/52wOT
Fantastic point! #IDSky #AMSsky
Unnecessary antibiotics contribute to greenhouse gas emmissions. Want to know how much? 👉🏻 shorturl.at/52wOT
Fantastic point! #IDSky #AMSsky
Reposted by SHORTEN-2 trial
Paper looking at how Avycaz (ceftazidime-avibactam) can select for cross resistance to other beta-lactam/beta-lactamase inhibitor combinations. @aleciarokes.bsky.social @vscooper.micropopbio.org @dariavantyne.bsky.social
Strong start to our P. aeruginosa research!
journals.asm.org/doi/10.1128/...
Strong start to our P. aeruginosa research!
journals.asm.org/doi/10.1128/...
Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa | Microbiology Spectrum
Antibiotic resistance is a significant challenge for physicians trying to treat infections. The development of novel antibiotics to treat resistant infections has not been prioritized for decades, limiting treatment options for infections caused by many ...
journals.asm.org
February 11, 2025 at 6:07 PM
Paper looking at how Avycaz (ceftazidime-avibactam) can select for cross resistance to other beta-lactam/beta-lactamase inhibitor combinations. @aleciarokes.bsky.social @vscooper.micropopbio.org @dariavantyne.bsky.social
Strong start to our P. aeruginosa research!
journals.asm.org/doi/10.1128/...
Strong start to our P. aeruginosa research!
journals.asm.org/doi/10.1128/...
Reposted by SHORTEN-2 trial
Are you a #Pseudomonas researcher? Please take our survey and help shape the direction and priority of future pseudomonas.com database development: forms.gle/gTPT6ruf3mqb...
#microsky #idsky
#microsky #idsky
The Pseudomonas Genome Database - Genome annotation and comparative genome analysis
pseudomonas.com
February 1, 2025 at 9:34 PM
Are you a #Pseudomonas researcher? Please take our survey and help shape the direction and priority of future pseudomonas.com database development: forms.gle/gTPT6ruf3mqb...
#microsky #idsky
#microsky #idsky
Can we use Ciprofloxacin for treating Levofloxacin-R Pseudomonas and viceversa? 🤔
#AMSsky #PsWatch 👇🏻👇🏻
#AMSsky #PsWatch 👇🏻👇🏻
Discordant Data? Don’t Despair! Check out this week’s KASIC pearl to learn about Discordant Susceptibility Results: Ciprofloxacin and Levofloxacin ➡️ kymdro.org/kasic/?p=8122
#IDSky #AntimicrobialResistance #antimicrobialstewardship #rxsky #pharmacy #FOAMed #NPs #PAs
#IDSky #AntimicrobialResistance #antimicrobialstewardship #rxsky #pharmacy #FOAMed #NPs #PAs
January 25, 2025 at 10:30 PM